New registry to reveal how blinatumomab works in everyday leukemia care
NCT ID NCT07117136
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is a registry that collects data from 200 adults with B-cell acute lymphoblastic leukemia who received blinatumomab as part of their treatment outside of a clinical trial. Researchers will look at how many patients achieve complete remission and overall survival. The goal is to understand real-world effectiveness and outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- blinatumomab
- What this could lead to
- If successful, this registry could provide real-world evidence on how well blinatumomab works outside clinical trials, potentially guiding better treatment decisions for B-ALL patients.
- What could go wrong
- This is an observational registry, not a controlled trial, so results may be influenced by patient selection and varying treatments. It does not test a new intervention or prove cause and effect.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic Cancer Center
RECRUITINGJacksonville, Florida, 32224, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Medical College of Wisconsin
RECRUITINGMilwaukee, Wisconsin, 53226, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Targeted drug aims to clear hidden leukemia before transplant
- Supercharged immune cells take aim at cancer and viruses in one shot
- Double-Pronged immune cells take aim at stubborn blood cancers
- Engineered immune cells take aim at Tough-to-Treat blood cancers
- Combination therapy aims to keep leukemia in check after transplant
- Dual-Pronged CAR T-Cell therapy takes aim at Hard-to-Treat leukemia